Format

Send to

Choose Destination
Pediatr Int. 2012 Aug;54(4):528-31. doi: 10.1111/j.1442-200X.2012.03603.x. Epub 2012 Apr 19.

Prophylaxis for ribavirin-related anemia using eicosapentaenoic acid in chronic hepatitis C patients.

Author information

1
Department of Pediatrics, Juntendo University School of Medicine, Tokyo, Japan. f-mitsuo@zc5.so-net.ne.jp

Abstract

BACKGROUND:

Ribavirin-related anemia is a serious side-effect of the pegylated interferon and ribavirin therapy used for hepatitis C, and may be cause for a reduction in ribavirin dose or even cessation of treatment. The aim of this study was to evaluate the prophylactic effects of oral eicosapentaenoic acid (EPA) supplementation on ribavirin-induced hemolytic anemia in pediatric and young adult patients.

METHODS:

Twelve chronic hepatitis C patients ranging in age from 3 to 21 years (mean, 13.9 ± 5.1 years) who received pegylated interferon α-2b and ribavirin combination therapy were randomized to either the control group (n = 6) or EPA group (n = 6). Blood samples were collected before, and at 4, 8, and 16 weeks after treatment to measure clinical laboratory parameters.

RESULTS:

The reduction in hemoglobin levels of the EPA group was significantly ameliorated at 8 and 16 weeks when compared to the control group (P < 0.05). There was no significant difference in plasma ribavirin concentrations between the two groups during the treatment. However, one patient in the control group had a reduction in ribavirin dose.

CONCLUSION:

EPA supplementation prevented ribavirin-induced hemolytic anemia during combination therapy with pegylated interferon α-2b and ribavirin in pediatric and young adult patients.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center